Beren Therapeutics Presents New Adrabetadex Data Showing Preservation of Neurological Function for More Than 10 Years in Children with Infantile-Onset NPC
A case study presented at Child Neurology Society Annual Meeting demonstrates preservation of neurological function in sisters with infantile-onset Niemann-Pick disease, type C Additional data presentations reinforce benefit of early and sustained adrabetadex treatment in preserving function and improving long-term outcomes THOUSAND OAKS, Calif. — Beren Therapeutics P.B.C., a leader in…
We haven't written up this one. Financial Post has the full story — the link below goes straight to it.
